How could we optimize the management of children with CNS demyelinating disorders in different resource settings?

ICNC2024
Symposia: What Is New In Pediatric CNS Demyelination?

How could we optimize the management of children with CNS demyelinating disorders in different resource settings?
Lekha Pandit

Appropriate management and treatment leading to disease control in CNS demyelinating disorders has the potential to alter the known trajectory of adverse long-term physical, cognitive, and psychosocial outcomes in this population. Thus, optimizing appropriate diagnosis and early treatment initiation for children and adolescents with NMOSD, MS, or MOGAD is of paramount importance. However, to reach this goal in resource-limited settings is challenging and will be discussed during this session.

Other Lectures in this symposium
Key MRI diagnostic features of MS, MOGAD and NMOSD
Diagnosing MOGAD in pediatric patients. Updated diagnostic criteria from an International Panel.
Progress in Pediatric MS Treatment: Real World Evidence with High-impact therapies